Three new investigational drugs have secured a place on the European Medicines Agency’s PRIME (priority medicines) scheme, including talquetamab and teclistamab, the bispecific antibodies that Janssen is developing to treat relapsed or refractory multiple myeloma.
ARU-1801, Aruvant Sciences’ one-time investigational gene therapy for sickle cell disease, is also among the latest product to win a place on the scheme, which was launched in 2016 to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?